Hepion pharmaceuticals to present phase 2a rencofilstat multiomics data at nash-tag 2023

Edison, n.j., jan. 05, 2023 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“nash”), hepatocellular carcinoma (“hcc”), and other chronic diseases, today announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented at the nash-tag 2023 conference, which is being held january 5-7, 2022, in park city, utah.
HEPA Ratings Summary
HEPA Quant Ranking